Concepts (68)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 4 | 2025 | 844 | 1.310 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 1689 | 1.270 |
Why?
|
| Glypicans | 1 | 2024 | 40 | 0.880 |
Why?
|
| Interleukin-15 | 1 | 2024 | 90 | 0.850 |
Why?
|
| Neoplasms | 5 | 2025 | 2814 | 0.830 |
Why?
|
| Hematologic Neoplasms | 2 | 2025 | 293 | 0.770 |
Why?
|
| Sarcoma, Ewing | 1 | 2019 | 110 | 0.560 |
Why?
|
| Cystic Fibrosis | 1 | 2019 | 262 | 0.500 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2024 | 1154 | 0.470 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2019 | 458 | 0.460 |
Why?
|
| Genetic Therapy | 1 | 2019 | 679 | 0.440 |
Why?
|
| Patient Safety | 1 | 2019 | 431 | 0.430 |
Why?
|
| Catheter-Related Infections | 2 | 2024 | 133 | 0.360 |
Why?
|
| Graft vs Host Disease | 2 | 2023 | 622 | 0.290 |
Why?
|
| Human Growth Hormone | 1 | 2025 | 76 | 0.230 |
Why?
|
| Growth Disorders | 1 | 2025 | 184 | 0.220 |
Why?
|
| beta-Thalassemia | 1 | 2023 | 26 | 0.210 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 51 | 0.200 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 51 | 0.190 |
Why?
|
| Interleukin-6 | 1 | 2024 | 404 | 0.190 |
Why?
|
| Burkitt Lymphoma | 1 | 2023 | 130 | 0.190 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 141 | 0.180 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2022 | 66 | 0.180 |
Why?
|
| Cancer Survivors | 1 | 2025 | 254 | 0.180 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 235 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 333 | 0.170 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 478 | 0.160 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 5079 | 0.160 |
Why?
|
| Cross Infection | 1 | 2022 | 333 | 0.150 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 65 | 0.150 |
Why?
|
| Humans | 13 | 2025 | 125613 | 0.150 |
Why?
|
| Child | 9 | 2025 | 25015 | 0.150 |
Why?
|
| Quality Improvement | 1 | 2024 | 673 | 0.140 |
Why?
|
| Sepsis | 1 | 2022 | 486 | 0.140 |
Why?
|
| Forecasting | 1 | 2019 | 348 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 786 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 452 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2024 | 4878 | 0.120 |
Why?
|
| Retrospective Studies | 5 | 2025 | 16725 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 710 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2002 | 0.090 |
Why?
|
| Genomics | 1 | 2019 | 1570 | 0.090 |
Why?
|
| Male | 4 | 2025 | 61966 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2019 | 3414 | 0.080 |
Why?
|
| Female | 4 | 2025 | 67790 | 0.080 |
Why?
|
| Infant | 4 | 2025 | 12758 | 0.070 |
Why?
|
| Child, Preschool | 4 | 2025 | 14316 | 0.070 |
Why?
|
| Prognosis | 2 | 2025 | 4668 | 0.060 |
Why?
|
| Cranial Irradiation | 1 | 2025 | 71 | 0.060 |
Why?
|
| Middle Aged | 1 | 2024 | 27263 | 0.060 |
Why?
|
| Oral Health | 1 | 2024 | 27 | 0.050 |
Why?
|
| Alemtuzumab | 1 | 2023 | 86 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2019 | 12334 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 46 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 142 | 0.050 |
Why?
|
| Adolescent | 3 | 2025 | 19904 | 0.050 |
Why?
|
| Chlorhexidine | 1 | 2022 | 45 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2023 | 637 | 0.050 |
Why?
|
| Transplantation Conditioning | 1 | 2023 | 303 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 102 | 0.050 |
Why?
|
| Adult | 1 | 2022 | 30189 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 417 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1403 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2022 | 575 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2022 | 465 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2023 | 6162 | 0.020 |
Why?
|
| Young Adult | 1 | 2025 | 9556 | 0.020 |
Why?
|
| United States | 1 | 2025 | 11141 | 0.020 |
Why?
|